| INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has become an innovative alternative procedure that enables catheter-based treatment in patients with severe aortic stenosis (AS) considered high-risk candidates for surgical treatment. [1] [2] Various access routes have been described in TAVI procedures and a trend in favour of the transfemoral (TF) approach was observed regarding 30-day mortality and 1-year mortality rates. [3] [4] Use of the percutaneous approach reduced major vascular complications, bleeding, and acute kidney injuries compared with the surgical cut-down approach. 5 Percutaneous TF-TAVI is a safer and less invasive approach and has become a mainstream treatment strategy in TAVI. The vascular closure device (VCD) is a necessary instrument that is used to achieve haemostasis in TF-TAVI in this era. [6] [7] [8] [9] There are a few complications peculiar to the use of the Perclose ProGlide® suture-mediated closure system (Abbott Vascular, Santa Clara, CA), such as dissection, acute femoral artery stenosis or occlusion, bleeding, and device failure. The mechanism of ProGlide complications has not been fully elucidated, but blind ProGlide operation within the vessel would be associated with the uncertainty.
We found that the use of real-time echography could clearly reveal this process. In this study, we assessed the efficacy of the novel Echoguided ProGlide technique using echography and the ProGlide in patients who underwent TF-TAVI.
| MATERIALS AND METHODS

| Patient population
The patient population is shown in Figure 1 . In our hospital, 171 patients underwent TAVI between February 2014 and July 2017. In this study, patients underwent TAVI using the balloon-expandable Edwards SAPIEN XT (SXT) or SAPIEN S3 (S3) valve (Edwards Lifesciences, Irvine, CA) and the self-expandable Medtronic CoreValve
Revalving System (Medtronic Inc., Minneapolis, MN). After the exclusion of patients who underwent the non-TF approach (n = 35) and the TF approach with surgical cut-down approach (n = 15), a total of 121 patients who underwent TF-TAVI using the ProGlide were enrolled in this study. 
| Echo-guided ProGlide technique
The initial step of the Echo-guided ProGlide technique was echoguided puncture. We checked the common femoral artery and femoral artery bifurcation on the short-and long-axis views and identified the puncture point without calcification or atherosclerotic plaque. Under real-time echo guidance, we punctured only the anterior vessel wall at this point ( Figure 2) . A regular 0.035-inch guidewire was inserted from a puncture site at the common femoral artery, the ProGlide device was inserted, significant blood return was confirmed, a "foot" developed, and the device was withdrawn until the "foot" abutted the arterial wall and blood return stopped. Before the needle plunger was depressed, we pushed and pulled the device and checked the motion of both arterial walls ( Figure 3 ). If the ProGlide did not operate appropriately, the "foot" interfered with the posterior wall motion and could induce acute femoral artery occlusion and ProGlide failure. If abnormal motion was found, we pushed the system into the vessel until blood flow returned, folded the "foot," rotated it a little, and attempted the sequential procedure again. After optimal ProGlide motion was confirmed, we depressed the needle plunger and deployed the suture knot outside the skin.
After the aortic valve deployment and sheath removal, the suture knot was advanced with the knot pusher and tied down. Manual 
| Assessment of vascular access and definition
All access routes were assessed by enhanced multi-detector row computed tomography (MDCT). The minimal lumen diameter (MLD) of the iliofemoral arteries was measured. Vessel tortuosity and calcifications were evaluated using MDCT as previously described. 7, 10 Tortuosity was graded as none, mild (30-60°), moderate (60-90°), or severe (>90°). MDCT calcification was graded as none, mild (some calcification), moderate (the arterial course can be seen without contrast dye injection), or severe (heavily calcified iliofemoral arteries). [11] [12] The sheath to femoral artery ratio (SFAR) was defined as the ratio between the sheath outer diameter and the femoral artery MLD, while the unexpanded sheath diameter was used for the calculation. 
| Clinical endpoints
The efficacy endpoints of this study were major or minor vascular complication, acute femoral artery stenosis or occlusion, and ProGlide failure. ProGlide failure included access site bleeding requiring a surgical procedure or endovascular ballooning to achieve haemostasis. 
| RESULTS
| Patient characteristics and procedural variables
The patients' backgrounds are shown in Table 1 . Cardiac risk factors, comorbidities, and prescribed medications were similar between the 
| Procedural outcomes and complications
Procedural outcomes and in-hospital outcomes are shown in Table 4 .
Procedure and fluoroscopy times were significantly shorter and contrast media use was significantly smaller in the echo-guided group.
The incidence of major vascular complications per VARC-2 criteria was higher in the not echo-guided group (1.6% vs 10.7%, P = 0.002). One iliac artery perforation, two iliac artery dissections, and six femoral artery stenoses or occlusions occurred and were treated with endovascular therapy. Two cases of femoral bleeding were treated surgically. Regarding access site complications, acute femoral stenosis or occlusion was less commonly seen in the echo-guided group (0% vs 10.3%, P < 0.003). The incidence of ProGlide failure was similar between the two groups (1.6%. vs 5.2%, P = 0.26). ProGlide complications were significantly rarer in the echo-guided group (1.6% vs 15.5%, P = 0.003). 
| Clinical predictors of ProGlide complications
| DISCUSSION
To the best of our knowledge, this study is the first to report on the use of the Echo-guided ProGlide technique in patients undergoing percutaneous TF-TAVI. The important finding of this study was that this novel technique demonstrated a reduction in major vascular complications, particularly ProGlide-related complications in patients undergoing TF-TAVI. The femoral artery was the most common site of vascular complications and the ProGlide played a key role in the prevention of femoral artery complications. 5 The incidence of ProGlide complications reported in other TAVI series ranged from 3.4% to 8%. Using the Echo-guided ProGlide technique, the incidence of ProGlide complications decreased to 1.6% and no cases of acute femoral artery occlusion or stenosis were observed. In the one case of ProGlide failure in the echo-guided group, the suture became intertangled with the skin when suture knot was advanced with the knot pusher after valve deployment and sheath removal. We also observed optimal ProGlide operation within the vessel using echography in this case. Visualization of the ProGlide operation within the vessel using echography was an epoch-making but simple technique. Hayashida et al reported experience reduced major vascular complications, 7 but introduction of Echoguided ProGlide technique could be helpful to reduce complications even in early experienced centers.
Echo-guided femoral artery access is reportedly related with a lower rate of access site complications during peripheral vascular intervention. 16, 17 We could visualize the femoral artery bifurcation or arterial wall calcification using echography. Therefore, echo-guided puncture enables detection of the optimal femoral arteriotomy site or avoidance of puncture at the calcified site to prevent complications. 18, 19 Rather than the Seldinger method, we used direct puncture with real-time navigation to minimize arterial wall injury. After creating the optimal puncture, we confirmed optimal ProGlide operation within the vessel and instantly noted abnormal findings that would lead to
ProGlide-related complications.
In the current study, we used ProGlide as VCD in all cases. The
Prostar XL suture-mediated closure systems are also widely used to achieve haemostasis after TF-TAVI. Some studies compared the effectiveness of the Prostar and ProGlide, but the results were controversial. 9, 20, 21 These studies underline the importance of the use of an optimal deployment technique. The echo-guided technique described here satisfied the requirements and was useful even with the Prostar XL, but this point should be assessed in other cohort studies. The single and double ProGlide techniques have been used during TF-TAVI but the superiority remains controversial. [22] [23] [24] In a recent study, the Some studies reported that sheath size was an independent risk factor for vascular complications after TAVI. 11, 25 On the other hand, no reduction in vascular complications was observed after S3 versus SXT implantation. 26 In our study, sheath size was significantly smaller in the echo-guided group due to S3 introduction, but SFAR did not differ between the echo-guided and not echo-guided groups. This result could be attributed to the indication for the TF approach being expanded for patients with a more narrow access route and the reduced sheath size of the S3 transcatheter heart valve. Actually, the patients enrolled in the echo-guided group, 90% of whom underwent S3 implantation, had small femoral artery diameters compared with patients enrolled in the not echo-guided group, all of whom underwent SXT implantation. Previous studies reported a positive correlation between SFAR and the risk of vascular complications during TF-TAVI. 13, 15 In this study, only the echo-guided procedure was an independent predictor of ProGlide complications. In this study, the and cost effective, which will make TF-TAVI a safer and less invasive procedure.
| Study limitations
There were some limitations to the study. To maximize the elimination of any unmeasured confounders and selection bias, we assessed consecutive all patients who underwent percutaneous TF-TAVI;
however, this was a single-center observational study. This study design and small sample size could have led to bias in the results.
This echo-guided technique was introduced in March 2016; thus, the enrolment period differed between the echo-guided and not echoguided groups so that we could not excluded the influence caused by introduction of innovative technology such as advanced valves or sheaths and so on.
Further studies with a larger sample sizes including multi-center are required to assess the efficacy of Echo-guided ProGlide technique during TF-TAVI.
| CONCLUSION
In this study, we assessed the safety and efficacy of Echo-guided 
